Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Hospital Clínic of Barcelona, shared a post on LinkedIn:
“New Publication from Our Lab!
We are excited to share our latest study, now published in ESMO Open:
Genomic and clinical features in young women with ER+/HER2- breast cancer.
Read more here.
This work, led by Benjamin Walbaum and Maria Vidal, addresses a critical question in breast oncology:
Why do young women (≤40 years) with ER+/HER2– early breast cancer have worse outcomes, even when treated intensively?
Key findings:
- Young women had a higher recurrence risk compared to older patients.
- Ki67 and IHC subtypes failed to predict prognosis in this group.
- Genomic profiling revealed lower estrogen signaling and higher basal-like gene expression in younger women.
- Importantly, the ROR (risk of recurrence) score provided strong prognostic value and improved risk stratification.
These results highlight that age matters biologically in ER+/HER2– breast cancer and that genomic testing adds value beyond conventional biomarkers in guiding treatment for young patients.
Congratulations to the entire team for this impactful contribution, and especially to Benjamin Walbaum and Maria Vidal for their leadership.”
More from Aleix Prat on OncoDaily.